Mitigating cellular inflammation in older adults: a randomized controlled trial of Tai Chi Chih

Am J Geriatr Psychiatry. 2012 Sep;20(9):764-72. doi: 10.1097/JGP.0b013e3182330fd3.

Abstract

Objectives: To evaluate the effects of a behavioral intervention, Tai Chi Chih (TCC) on circulating markers of inflammation in older adults.

Design: A prospective, randomized, controlled trial with allocation to two arms, TCC and health education (HE), 16 weeks of intervention administration, and 9 weeks follow-up.

Participants: A total of 83 healthy older adults, aged 59 to 86 years.

Measurements: The primary endpoint was circulating levels of interleukin 6 (IL-6). Secondary outcomes were circulating levels of C-reactive protein, soluble IL-1 receptor antagonist, soluble IL-6 receptor, soluble intercellular adhesion molecule, and IL-18. Severity of depressive symptoms, sleep quality, and physical activity was also assessed over the treatment trial.

Results: Among those older adults with high levels of IL-6 at entry, a trend for a treatment group by time interaction was found (F[1,70] = 3.48, p = 0.07), in which TCC produced a drop of IL-6 levels comparable to those found in TCC and HE subgroups who had low levels of IL-6 at entry (t72's = 0.80, 1.63, p's >0.10), whereas IL-6 in HE remained higher than the TCC and HE subgroups with low entry IL-6 (t72 = 2.47, p = 0.02; t72 = 1.71, p = 0.09). Decreases in depressive symptoms in the two treatment groups correlated with decreases of IL-6 (r = 0.28, p <0.05). None of the other cellular markers of inflammation changed in TCC versus HE.

Conclusion: TCC can be considered a useful behavioral intervention to reduce circulating levels of IL-6 in older adults who show elevated levels of this inflammatory marker and are at risk for inflammation-related morbidity.

Trial registration: ClinicalTrials.gov NCT00118885.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Depression / blood
  • Depression / complications
  • Depression / therapy
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / complications
  • Inflammation / psychology*
  • Inflammation / therapy*
  • Intercellular Adhesion Molecule-1 / metabolism
  • Interleukin 1 Receptor Antagonist Protein / metabolism
  • Interleukin-18 / metabolism
  • Interleukin-6 / metabolism*
  • Male
  • Middle Aged
  • Motor Activity
  • Patient Compliance / statistics & numerical data
  • Receptors, Interleukin-6 / metabolism
  • Sleep / physiology
  • Tai Ji / methods*
  • Tai Ji / statistics & numerical data

Substances

  • Biomarkers
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-18
  • Interleukin-6
  • Receptors, Interleukin-6
  • Intercellular Adhesion Molecule-1
  • C-Reactive Protein

Associated data

  • ClinicalTrials.gov/NCT00118885